[ADMS] Adamas Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 17.42 Change: 0.78 (4.69%)
Ext. hours: Change: 0 (0%)

chart ADMS

Refresh chart

Strongest Trends Summary For ADMS

ADMS is in the long-term up 49% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company?s lead product candidate, ADS-5102, is being developed for a complication of Parkinson?s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.84 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -99.1% Sales Growth - Q/Q-99.25% P/E-6.16
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA2.99% ROE3.2% ROI
Current Ratio14.25 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin21.43% Net Profit Margin7.87% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities-18.45 M Cash From Operating Activities-14.06 M Gross Profit
Net Profit-12.2 M Operating Profit-12.23 M Total Assets147.34 M Total Current Assets115.52 M
Total Current Liabilities8.11 M Total Debt Total Liabilities9.79 M Total Revenue230 K
Technical Data
High 52 week42.65 Low 52 week13.68 Last close24.16 Last change1.6%
RSI32.36 Average true range1.15 Beta1.4 Volume92.31 K
Simple moving average 20 days-7.54% Simple moving average 50 days-9.49% Simple moving average 200 days-16.87%
Performance Data
Performance Week-9.55% Performance Month-6.25% Performance Quart-19.33% Performance Half-36.15%
Performance Year40.71% Performance Year-to-date-28.71% Volatility daily2.85% Volatility weekly6.37%
Volatility monthly13.05% Volatility yearly45.2% Relative Volume208.74% Average Volume562.48 K
New High New Low

News

2019-06-25 08:10:12 | Will Adamas Pharmaceuticals Continue to Surge Higher?

2019-06-21 10:37:02 | Bausch Health BHC Catches Eye: Stock Jumps 6.2%

2019-06-20 09:56:48 | Should You Worry About Adamas Pharmaceuticals, Inc.'s NASDAQ:ADMS CEO Salary Level?

2019-06-20 09:51:01 | Allergan AGN in Focus: Stock Moves 6.2% Higher

2019-06-19 07:51:49 | The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

2019-06-18 16:05:10 | Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson’s Disease

2019-06-18 09:00:01 | What Makes Adamas ADMS a New Buy Stock

2019-06-17 17:54:00 | ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.

2019-06-17 17:23:57 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.

2019-06-12 20:20:00 | INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-06-12 19:05:15 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-06-11 13:00:00 | SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-06-10 19:02:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-06-10 14:15:00 | IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-06-10 09:00:00 | ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.

2019-06-07 18:20:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-06-07 17:30:00 | Adamas Announces New Employment Inducement Grant

2019-06-04 11:49:48 | ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-06-03 20:20:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-06-03 18:00:00 | ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm

2019-06-03 16:31:00 | Adamas to Present at Upcoming JMP Investor Conference

2019-05-31 11:45:18 | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-05-30 19:03:29 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-05-30 18:31:23 | ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm

2019-05-30 16:30:00 | Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer 

2019-05-29 10:32:00 | INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-05-29 10:23:00 | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adamas Pharmaceuticals, Inc. ADMS

2019-05-28 21:00:00 | Bragar Eagel & Squire, P.C. is Investigating Adamas Pharmaceuticals, Inc. NASDAQ: ADMS on Behalf of Adamas Stockholders and Encourages Adamas Investors to Contact the Firm

2019-05-28 17:55:01 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.

2019-05-28 15:58:00 | INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-05-28 14:28:00 | EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Adamas Pharmaceuticals, Inc. – ADMS

2019-05-24 20:17:00 | ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.'s January 24, 2018 Secondary Public Offering To Contact The Firm

2019-05-24 16:08:50 | EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.

2019-05-23 17:44:00 | Robbins Arroyo LLP: Complaint Alleges that Adamas Pharmaceuticals Inc. ADMS Misled Shareholders

2019-05-14 09:00:01 | Adamas ADMS Upgraded to Buy: Here's Why

2019-05-13 11:14:54 | Adamas to Present at Upcoming BAML Investor Conference

2019-05-10 00:33:06 | Edited Transcript of ADMS earnings conference call or presentation 9-May-19 8:30pm GMT

2019-05-09 19:05:11 | Adamas Pharmaceuticals ADMS Reports Q1 Loss, Lags Revenue Estimates

2019-05-09 18:02:28 | Adamas: 1Q Earnings Snapshot

2019-05-09 16:03:00 | Adamas Reports First Quarter 2019 Financial Results

2019-05-06 21:39:10 | Adamas Announces Data Presentations at the 71st American Academy of Neurology Annual Meeting

2019-04-25 10:34:02 | Will Adamas Pharmaceuticals ADMS Report Negative Q1 Earnings? What You Should Know

2019-04-22 15:00:00 | New Electric Vehicles Contain Much More Lithium

2019-04-22 14:46:13 | Before You Buy Adamas Pharmaceuticals, Inc. NASDAQ:ADMS, Consider Its Volatility

2019-03-12 16:05:00 | Adamas Announces New Employment Inducement Grant

2019-03-05 12:40:00 | Why Adamas Pharmaceuticals Shares Are Crashing Today

2019-03-05 07:24:27 | The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings

2019-03-04 21:51:27 | Edited Transcript of ADMS earnings conference call or presentation 4-Mar-19 9:30pm GMT

2019-03-04 21:34:12 | Adamas Pharmaceuticals Inc ADMS Q4 2018 Earnings Conference Call Transcript

2019-03-04 16:35:42 | Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018